FlyWorks

FlyWorks is a biotechnology company that provides a platform for efficient drug discovery and development based on the use of Drosophila, commonly known as the fruit fly. By leveraging genetically similar models, the company offers services such as drug discovery support, alternative safety testing, and the licensing of lead compounds. These Drosophila-based models are utilized as a cost-effective, high-throughput, and ethical alternative to traditional mammalian testing, addressing challenges in fields ranging from pharmaceuticals to food and cosmetic product development. The platform is designed to conduct large-scale, individual-level genetic and chemical screenings, facilitating the identification of disease-causing signaling networks and therapeutic drug candidates for conditions such as cancer, heart disease, and diabetes. Established through collaborative research from institutions including Hokkaido University, the University of Tokyo, and the Icahn School of Medicine at Mount Sinai, the company is backed by various Japanese research programs and has expanded its presence internationally. By enabling automated, high-content screening, FlyWorks provides research and development support to corporate clients, helping them accelerate the discovery of new therapeutic treatments and improve innovation cycles while reducing the need for costly and time-consuming conventional animal models.